Fenbendazole and Cancer: What Recent Research — and Real People — Are Revealing

After reviewing a research paper and watching two eye-opening videos, I share my personal exploration of Fenbendazole’s potential for healing and integrative care.

This article began with curiosity. After reading a fascinating research paper about Fenbendazole (see further) and watching two eye-opening videos, I wanted to understand more. This familiar antiparasitic drug suddenly appeared in a completely different light — connected to stories of healing, scientific debate, and new perspectives on what might support the body in its recovery process.

In this post, I’ll take you along as I explore Fenbendazole a little more deeply — what science has uncovered so far, what people have experienced, and why it has captured so much attention. In my next article, I’ll focus more closely on Ivermectin, to see how this repurposed drug fits into this broader conversation.

Please note: this article is meant purely as information and reflection. It is not a replacement for conventional medical treatment, but rather an invitation to consider how certain alternative insights might be combined thoughtfully with mainstream medicine — in the spirit of a more holistic, open-minded approach to healing.

Curiosity can open unexpected doors — and sometimes, that’s where real discovery begins.

The research paper featured in Case Reports in Oncology (2025), three patients battling advanced cancers—breast, prostate, and melanoma—took it upon themselves to try Fenbendazole alongside their other treatments. To everyone's surprise, two of them achieved complete remission, while the third experienced an almost full recovery, all without any serious side effects. The researchers are telling us that lab studies have indicated that Fenbendazole might disrupt cancer cell growth by interfering with microtubules, halting cell division, and triggering apoptosis, which is the natural process of cell death. However, they also warned that these findings stem from individual cases rather than formal clinical trials. You can read the research paper here: https://karger.com/cro/article-pdf/18/1/856/4381509/000546362.pdf)

And then I discovered these two surprising 'eye-opening' videos. Dr. John Campbell created a YouTube channel and has, at present, 3.27 million followers! In his videos, he discusses health science topics, nursing education, and, more recently, public health issues.

The first video on Fenbendazole (Nov. 10, 2025—see below) got almost 367,000 views.

John tells us in the second video (Nov.14), again 74,000 views in one day, some of the comments he got following the first video.

I totally get that even if you have a mountain of 100,000 testimonials singing the praises of a repurposed drug, it’s really just a strong hint—not definitive proof. Without solid data, controlled studies, and research that’s been peer-reviewed, these stories, no matter how uplifting, are still just anecdotes. And let’s be honest, big pharmaceutical companies probably won’t throw their weight behind drugs like this—there’s no patent protection, no long-term monopoly, and the profit margins just aren’t appealing. Regulatory exclusivity is pretty limited; insurers aren’t going to shell out for old, cheap compounds, and governments rarely back such trials. So, we’re left with small studies and the experiences of those who have actually tried these medications themselves.

From that perspective, I began to look more closely at what science actually does say about Fenbendazole. What struck me was that this drug, originally developed to treat parasites in animals, has shown some unexpected properties in laboratory studies. Researchers discovered that it can slow down the growth of cancer cells by disrupting their internal structure, stopping cell division, and encouraging damaged cells to die off naturally. Although most of this comes from preclinical studies—meaning research done in labs and on animals—it appears that Fenbendazole may influence biological processes that could also be relevant in humans.

So we’re left with small studies and the voices of those who have tried these medicines for themselves. Still, when someone is told they have only a few months to live, the question naturally arises: what do they have to lose? Especially when a repurposed drug like Fenbendazole has shown such a low risk of side effects and offers even a possibility for improvement — or simply, a reason to keep hoping.

Hope is a potent force—sometimes even more powerful than any medicine. When people find themselves in situations where traditional treatments have run their course, something deep within often stirs: a quiet resolve to try, to believe, to seek out what might still be achievable. I’ve witnessed this spirit before—in stories of healing that seem almost miraculous, in moments when intuition leads the way in ways that science hasn’t yet understood. Maybe healing isn’t always about having all the answers but rather about being open—ready to follow a path that feels right, even if it’s not completely clear.

Noël

Here are several research papers and studies that have reported positive findings (in vitro, in vivo or case‐series) for Fenbendazole and its anticancer potential. Please note that positive findings here do not equate to clinical proof of efficacy in humans — many are early stage.

YearCitationBrief summary of findings2024 Wang X et al., Transcriptome analysis reveals the anticancer effects of FBZ in ovarian cancer (BMC Cancer)

BioMed CentralIn ovarian cancer models (in vitro + xenograft mouse model) FBZ reduced tumour size/weight, induced cell‐cycle arrest in G2/M, and apoptosis/mitotic catastrophe.2025Lei X et al., Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer (Molecules)

MDPIFBZ inhibited proliferation of multiple human cancer cell lines (including HeLa cervical cancer cells) and even cancer stem‐cell–like populations (CCSCs); showed tumour growth inhibition in xenograft models.2025Makis W., Baghli I., Martinez P., Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients (Case Rep Oncol)

Karger Publishers+1Three human patients with advanced cancer used FBZ (self-administration, alongside other therapies). Two achieved complete remission and one near-complete remission. Authors emphasise anecdotal status and call for clinical trials.2025Nguyen TQ et al., Synergistic anti-tumor effect of fenbendazole and DADA in NSCLC (Transl Lung Cancer Res)

tlcr.amegroups.orgIn a non-small cell lung cancer (NSCLC) xenograft mouse model, FBZ combined with diisopropylamine dichloroacetate (DADA) showed enhanced tumour-inhibition and better safety profile compared to FBZ alone.2024Nguyen J et al., Oral Fenbendazole for Cancer Therapy in Humans and Animals (Anticancer Research)

ar.iiarjournals.orgA review/meta‐analysis‐style article summarizing preclinical evidence of FBZ’s anticancer activity across many cancer types; highlights potential but notes lack of robust human clinical trial data.